Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biotricity Inc (NQ: BTCY )

0.4631 UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.4631
Bid (Size) 0.4300 (2)
Ask (Size) 0.4400 (5)
Prev. Close 0.4631
Today's Range 0.4631 - 0.4631
52wk Range 0.4631 - 1.670
Shares Outstanding 22,454,644
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
SWK Holdings Provides Portfolio Update
Via ACCESSWIRE
Biotricity Provides Updated Guidance for Earlier than Expected Path to Profitability due to Growing Revenues and Improving Margins
Via ACCESSWIRE

Performance

YTD
-60.76%
-60.76%
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
-62.20%
-62.20%
1 Year
-44.20%
-44.20%

More News

Read More
Biotricity Announces Inclusion as a Supplier to A Prominent Medical System That Services 21 States
Via ACCESSWIRE
Biotricity Kicks off Another Pilot Program with a Major Hospital System that Services over 800K Individuals
Via ACCESSWIRE
Biotricity Reports Continued Margin Improvement and Reduced Losses in its First Quarter Fiscal Year 2025
Via ACCESSWIRE
BTCY Stock Earnings: Biotricity Reported Results for Q1 2025
Via InvestorPlace
Biotricity Launches HeartSecure: Immediate, At-Home Cardiac Screening Now Available
Via ACCESSWIRE
Biotricity Provides Year-End Guidance with Expectations to Meet Analyst Revenue Target and Beating Loss and Margin Targets
Via ACCESSWIRE
LOBO EV and Nexalin Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
Biotricity Announces Continued Margin Improvement Driven by its Proprietary AI Cloud
Via ACCESSWIRE
Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
SWK Holdings Highlights Recent Achievements and Provides Portfolio Update
Via ACCESSWIRE
Biotricity and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
Biotricity Announces Accelerated Path to EBITDA Positive
Via ACCESSWIRE
Biotricity Adds 60-Site, Multi-State Hospital Cardiac Monitoring Pilot Program
Via ACCESSWIRE
BTCY Stock Earnings: Biotricity Beats EPS, Misses Revenue for Q4 2024
Via InvestorPlace
Biotricity Reports Strong Results with Revenue Growth, Continued Margin Improvement, and Reduced Operating Expenses for Fiscal Year 2024, Accelerating the Company's Path to Profitability
Via ACCESSWIRE
Biotricity to Host Fourth Quarter and Fiscal Year 2024 Financial Results and Business Update Call on June 27
Via ACCESSWIRE
Biotricity Launches Direct-to-Consumer Heart Health Screening Service, HeartSecure, Making Heart Health Services Accessible in Response to the #1 Global Killer, Poising Company to Access the Growing Home Diagnostics Market
Via ACCESSWIRE
Biotricity Preferred Shareholders Show Increased Commitment and Support of the Company by Converting Almost All Preferred A Shares into Restricted Common Stock
Via ACCESSWIRE
Biotricity Announces the Upcoming Launch of the First-Ever Direct-to-Patient Cardiac Screening Service, Targeting the $1.05B Home Heart Health Market
Via ACCESSWIRE
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Biotricity Expands Market Reach to Pulmonary and Neurology Fields Through Latest Partnerships with Two Leading Home-Based Diagnostic Companies
Via ACCESSWIRE
Biotricity's Path Towards Breakeven Accelerated by Latest Diagnostic Product, Biotres Pro, Garnering Rapid Interest from Existing and New Customers
Via ACCESSWIRE
Biotricity Launches Major Cardiac Monitoring Pilot Program in a Hospital System Comprised of 9 Hospitals and 10 Clinics
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.